Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas van As

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics|April 18, 2026
The PACE Trials: A Decade of Progress and the Lessons LearnedNicholas van As, Emma Hall
The New England Journal of Medicine|January 8, 2025
Stereotactic Body Radiotherapy in Localized Prostate Cancer. ReplyNicholas van As, Jaymini Patel, Emma Hall
Radiation Oncology (London, England)|October 4, 2013
Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?Alison Tree, Caroline Jones, Aslam Sohaib, et al.
The Lancet. Oncology|December 5, 2019
Optimal patient selection for stereotactic body radiotherapy - Authors' replyDouglas H Brand, Alison C Tree, Emma Hall, et al.
The Lancet. Oncology|August 8, 2015
Surgery versus SABR for resectable non-small-cell lung cancerCharles Dearman, Nicholas van As, Adrian Crellin, et al.
BJU International|June 3, 2011
Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancerAsim Afaq, Dow-Mu Koh, Anwar Padhani, et al.
The Lancet. Oncology|April 1, 2021
Stereotactic radiotherapy and oligometastases - Authors' replyAnastasia Chalkidou, Hannah Patrick, Matthew Q Hatton, et al.
BJR Open|November 28, 2024
The quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implicationsHoda Abdel-Aty, Nabil Hujairi, Iain Murray, et al.
JCO Oncology Practice|August 26, 2020
Squamous Non-Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of <i>TMPRSS2-ERG</i> Translocation With <i>SOX2</i> AmplificationNadza Tokaca, Wanyuan Cui, Stephen Hazell, et al.
Cancers|February 25, 2023
The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B StudyRagu Ratnakumaran, Victoria Hinder, Douglas Brand, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|April 18, 2026
The PACE Trials: A Decade of Progress and the Lessons LearnedNicholas van As, Emma Hall
The New England Journal of Medicine|January 8, 2025
Stereotactic Body Radiotherapy in Localized Prostate Cancer. ReplyNicholas van As, Jaymini Patel, Emma Hall
Radiation Oncology (London, England)|October 4, 2013
Prostate stereotactic body radiotherapy with simultaneous integrated boost: which is the best planning method?Alison Tree, Caroline Jones, Aslam Sohaib, et al.
The Lancet. Oncology|December 5, 2019
Optimal patient selection for stereotactic body radiotherapy - Authors' replyDouglas H Brand, Alison C Tree, Emma Hall, et al.
The Lancet. Oncology|August 8, 2015
Surgery versus SABR for resectable non-small-cell lung cancerCharles Dearman, Nicholas van As, Adrian Crellin, et al.
BJU International|June 3, 2011
Clinical utility of diffusion-weighted magnetic resonance imaging in prostate cancerAsim Afaq, Dow-Mu Koh, Anwar Padhani, et al.
The Lancet. Oncology|April 1, 2021
Stereotactic radiotherapy and oligometastases - Authors' replyAnastasia Chalkidou, Hannah Patrick, Matthew Q Hatton, et al.
BJR Open|November 28, 2024
The quantitative impact of prostate-specific membrane antigen (PSMA) PET/CT staging in newly diagnosed metastatic prostate cancer and treatment-decision implicationsHoda Abdel-Aty, Nabil Hujairi, Iain Murray, et al.
JCO Oncology Practice|August 26, 2020
Squamous Non-Small-Cell Lung Cancer Molecularly Reclassified as Transdifferentiated Prostate Cancer Due to Identification of <i>TMPRSS2-ERG</i> Translocation With <i>SOX2</i> AmplificationNadza Tokaca, Wanyuan Cui, Stephen Hazell, et al.
Cancers|February 25, 2023
The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B StudyRagu Ratnakumaran, Victoria Hinder, Douglas Brand, et al.
Pageof 6